Pfizer Inc.

A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS

A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS secchiarolim Wed, 07/15/2026 - 14:08 PF-07926307 (Combination COVID-19 and Influenza modRNA Vaccine) PHASE…

An Interventional, Open-Label, Randomized, Multicenter, Phase 2 Study of PF-07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older With Hormone Receptor-Positive, HER2-Negative Breast Cancer in The Neoadjuvant Settin

An Interventional, Open-Label, Randomized, Multicenter, Phase 2 Study of PF-07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older With Hormone Receptor-Positive, HER2-Negative Breast Cancer in The Neoadjuvant Settin soansm01 Fri, 06/26/2026 - 04:52…

Final Report: A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Pregnant Participants Living with HIV and Their Inf

Final Report: A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Pregnant Participants Living with HIV and Their Inf chavak11 Wed, 06/10/2026 - 06:28 Abrysvo …

A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use soansm01 Wed, 06/10/2026 - 02:23 Nurtec® ODT Rimegepant PHASE IV Tue, 10/18/2022 - 12:00 Tue, 06/10/2025 - 12:00…

C5041006 sub study 4

C5041006 sub study 4 amsdenmb Mon, 06/08/2026 - 16:39 Velsipity etrasimod PHASE II/III Mon, 01/06/2020 - 12:00 Mon, 06/09/2025 - 12:00 NCT04173273 C5041006 SS4 Public Disclosure Synopsis.pdf (105.28 KB) N https://clinicaltrials.gov/study/NCT04173273?term=c5041006&viewType=Card&rank=1 …

C5041006 sub study 3

C5041006 sub study 3 amsdenmb Mon, 06/08/2026 - 16:21 Velsipity etrasimod PHASE II/III Mon, 01/06/2020 - 12:00 Mon, 06/09/2025 - 12:00 NCT04173273 C5041006 SS3 Public Disclosure Synopsis.pdf (160.8 KB) N https://clinicaltrials.gov/study/NCT04173273?term=c5041006&viewType=Card&rank=1 …